Kim HT - Search Results

1

Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study.

Shah MA, Kojima T, Hochhauser D, Enzinger P, Raimbourg J, Hollebecque A, Lordick F, Kim SB, Tajika M, Kim HT, Lockhart AC, Arkenau HT, El-Hajbi F, Gupta M, Pfeiffer P, Liu Q, Lunceford J, Kang SP, Bhagia P, Kato K. Shah MA, et al. Among authors: kim sb, kim ht. JAMA Oncol. 2019 Apr 1;5(4):546-550. doi: 10.1001/jamaoncol.2018.5441. JAMA Oncol. 2019. PMID: 30570649 Free PMC article. Clinical Trial.

2

Phase II study of weekly paclitaxel and capecitabine in patients with metastatic or recurrent esophageal squamous cell carcinoma.

Yun T, Han JY, Lee JS, Choi HL, Kim HY, Nam BH, Kim HT. Yun T, et al. Among authors: kim hy, kim ht. BMC Cancer. 2011 Sep 2;11:385. doi: 10.1186/1471-2407-11-385. BMC Cancer. 2011. PMID: 21888637 Free PMC article. Clinical Trial.

3

A phase II trial of modified weekly irinotecan and cisplatin for chemotherapy-naïve patients with metastatic or recurrent squamous cell carcinoma of the esophagus.

Lee DH, Kim HT, Han JY, Lee SY, Yoon SJ, Kim HY, Lee JS. Lee DH, et al. Among authors: kim hy, kim ht. Cancer Chemother Pharmacol. 2008 Jan;61(1):83-8. doi: 10.1007/s00280-007-0450-7. Epub 2007 Apr 28. Cancer Chemother Pharmacol. 2008. PMID: 17468871 Clinical Trial.

4

Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study.

Ahn MJ, Han JY, Lee KH, Kim SW, Kim DW, Lee YG, Cho EK, Kim JH, Lee GW, Lee JS, Min YJ, Kim JS, Lee SS, Kim HR, Hong MH, Ahn JS, Sun JM, Kim HT, Lee DH, Kim S, Cho BC. Ahn MJ, et al. Among authors: kim dw, kim sw, kim s, kim js, kim hr, kim ht, kim jh. Lancet Oncol. 2019 Dec;20(12):1681-1690. doi: 10.1016/S1470-2045(19)30504-2. Epub 2019 Oct 3. Lancet Oncol. 2019. PMID: 31587882 Clinical Trial.

5

First-line gefitinib treatment for patients with advanced non-small cell lung cancer with poor performance status.

Lee YJ, Kim HT, Han JY, Yun T, Lee GK, Kim HY, Sung JH, Lee JS. Lee YJ, et al. Among authors: kim hy, kim ht. J Thorac Oncol. 2010 Mar;5(3):361-8. doi: 10.1097/JTO.0b013e3181cee1ea. J Thorac Oncol. 2010. PMID: 20107420 Free article.

6

Clinical evaluation of incadronate in korean patients with malignancy-associated hypercalcemia: An open-label, multicenter study.

Kim SB, Lee JS, Kim HT, Im YH, Kim TW, Ryoo BY, Park YH, Park JO, Park K, Katoh H, Yamamoto M. Kim SB, et al. Among authors: kim tw, kim ht. Curr Ther Res Clin Exp. 2007 May;68(3):193-204. doi: 10.1016/j.curtheres.2007.06.004. Curr Ther Res Clin Exp. 2007. PMID: 24683210 Free PMC article.

7

A Phase II Study of Weekly Paclitaxel Plus Gemcitabine as a Second-Line Therapy in Patients with Metastatic or Recurrent Small Cell Lung Cancer.

Yun T, Kim HT, Han JY, Yoon SJ, Kim HY, Nam BH, Lee JS. Yun T, et al. Among authors: kim hy, kim ht. Cancer Res Treat. 2016 Apr;48(2):465-72. doi: 10.4143/crt.2015.061. Epub 2015 May 26. Cancer Res Treat. 2016. PMID: 26044164 Free PMC article. Clinical Trial.

8

Phase II Study of Pemetrexed as a Salvage Chemotherapy for Thymidylate Synthase-Low Squamous Cell Lung Cancer.

Choi M, Kim HT, Han JY, Lee GK, Lee SH, Lim KY, Joo J, Won HJ, Lee JS, Lee Y. Choi M, et al. Among authors: kim ht. Cancer Res Treat. 2021 Jan;53(1):87-92. doi: 10.4143/crt.2020.741. Epub 2020 Aug 13. Cancer Res Treat. 2021. PMID: 32810931 Free PMC article. Clinical Trial.

9

Phase II study of weekly irinotecan plus capecitabine for chemotherapy-naive patients with advanced nonsmall cell lung carcinoma.

Han JY, Lee DH, Lee SY, Park CG, Kim HY, Lee HG, Lee JJ, Kim HT, Lee JS. Han JY, et al. Among authors: kim hy, kim ht. Cancer. 2005 Dec 15;104(12):2759-65. doi: 10.1002/cncr.21563. Cancer. 2005. PMID: 16294344 Free article. Clinical Trial.

10

Randomized phase 2 study of irinotecan plus cisplatin versus gemcitabine plus vinorelbine as first-line chemotherapy with second-line crossover in patients with advanced nonsmall cell lung cancer.

Han JY, Lee DH, Song JE, Lee SY, Kim HY, Kim HT, Lee JS. Han JY, et al. Among authors: kim hy, kim ht. Cancer. 2008 Jul 15;113(2):388-95. doi: 10.1002/cncr.23582. Cancer. 2008. PMID: 18484595 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,555 results

Search Page

Filters